The execution and management of Health Services Research projects can be an onerous task. Often there is no centralized body of knowledge within an organization around process and requirements. This leads to long execution timelines, difficulties with vendors and ultimately reduced productivity. The Collaborative Science Center of Excellence (CSCoE) was established in 2008 at Bristol-Myers Squibb (BMS) . This group manages the global operations of a wide variety of programs, a portion of which includes worldwide investigator sponsored research, non-clinical research, expanded access, and risk evaluation and mitigation programs. Beginning June 2009, operational management of the entire US Health Economics and Outcomes Research (HEOR) book of work was moved from the OR Scientists into the CSCoE. This included administration, contract execution, master service agreement negotiation, financial management, protocol writing, AMCP dossier updates, and invoice tracking and payment. Within the first year over 90 projects were migrated into the CSCoE. Benefits the Health Services Research group realized included: 1. A consolidated 2010 and planned 2011 book of work; 2. A reportable repository of project information; 3. HEOR protocol and AMCP dossier improvement through standardization of in-house scientific writing; 4. Expedited contract execution; 5. Innovative cost-sharing; 6. Tiered and batched review of contracts reduced corporate legal hours; 7. Rapid response to organizational queries. Centralized process management unlocked latent value by allowing OR Scientists to focus on value-added activities, increased organizational transparency and agility, and moved operations to a lower cost environment. 
POSTER SESSION I: DISEASE-SPECIFIC STUDIES Cardiovascular Disorders -Clinical Outcomes Studies

PCV1 DOES ROUTE OF ADMINISTRATION FOR ESTROGEN HORMONE THERAPY IMPACT RISK OF VENOUS THROMBOEMBOLISM: ESTRADIOL TRANSDERMAL SYSTEM VERSUS ORAL ESTROGEN-ONLY HORMONE THERAPY
OBJECTIVES:
To evaluate the risk of developing venous thromboembolism (VTE) events associated with the use of estradiol transdermal system (ETS; Vivelle-Dot®) relative to oral estrogen-only hormone therapy (HT) agents. METHODS: A health insurance claims analysis was conducted using the Thomson Reuters MarketScan database from January 2002 through October 2009. Patients Ն35 years old newly initiated on an ETS or oral estrogen-only HT with Ն2 dispensings were analyzed. VTE was defined as Ն1 diagnosis code for deep vein thrombosis or pulmonary embolism. As a secondary outcome we assessed incident VTE resulting in hospitalization. Cohorts of ETS and oral estrogen-only HT were matched 1:1 based on both exact factor and propensity score matching. Incidence rate ratio (IRR) was used to compare the rates of VTE between the matched cohorts. Remaining baseline imbalances from matching were included as covariates in multivariate adjustments. RESULTS: Among the matched ETS and oral estrogen-only HT users (27,018 subjects in each group), the mean (SD) ages of the cohorts were 48.9 (7.1) years; in each cohort 6,044 (22.4%) and 1,788 (6.6%) patients had a hysterectomy and an oophorectomy at baseline, respectively. The mean (median) drug exposure for the ETS and oral estrogen-only HT cohorts was 391 (264) and 401 (272) days, respectively. A total of 115 ETS users developed VTE compared to 164 subjects in the estrogen-only HT cohort (unadjusted IRR: 0.72; Pϭ0.006) . After adjustments, ETS remained statistically significantly associated with a lower incidence (33% reduction; Pϭ0.0134) of VTE. The incidence rate reduction for hospitalization-related VTE events among the ETS users was even more pronounced with the adjusted incidence being 62% lower for ETS users relative to oral estrogen-only HT users. CONCLUSIONS: Results of this large population-based study showed that patients receiving ETS had a significantly lower incidence of VTE compared to patients receiving oral estrogen-only HT. 
PCV2 THE RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIETARY CALCIUM AND VITAMIN D SUPPLEMENTS IN PATIENTS WITH OSTEOPOROSIS
OBJECTIVES:
Calcium and vitamin D supplements have been widely used and recommended for women to prevent or delay the onset of osteoporosis and the risk of bone fractures. Other benefits include the improvement of blood pressure and lipid levels and a lowering of body weight. In theory, the beneficial effects of calcium and vitamin D suggest improvements in cardiovascular health. Recent publications suggest the contrary and allude to increase serum calcium as a risk factor for adverse cardiovascular events. This study examines whether the exposure to these supplements are associated with cardiovascular events. METHODS: The study was based on California Medicaid (Medi-Cal) fee-for-service administrative claims data from January 1995 to December 2002. The study population consist of patients Ͼ50 years with recorded diagnoses of osteoporosis followed from diagnoses date to the end of eligibility. Patients were excluded for prior use of the supplements or diagnosis of cardiovascular events or drug induced osteoporosis. Propensity score matching based on age, gender, elixhauser comorbidities and eligibility data created case (nϭ 1594) and control groups (nϭ4782). Chi-square analysis was conducted for comparison of the cardiovascular events defined as ICD9 codes for myocardial infarction and searchable terms of "cerebral infarction, hemorrhage, ischemia" for stroke. RESULTS: No statistically significant relationship was found between the study groups for stroke (pϭ0.56) and myocardial infarction (pϭ0.54). Components of stroke included cerebral artery occlusion (pϭ0.94), precerebral artery occlusion (pϭ0.27), intracerebral hemorrhage (pϭ0.23), and subarachnoid hemorrhage (pϭ0.05). The clinical benefits of the supplements were evident with subarachnoid hemorrhage with 0 recorded diagnoses in the case group compared to 12 recorded diagnosis in the control group; however statistical significance was not established. CONCLUSIONS: The use of calcium and vitamin D supplementation yielded no relationship to the risk of adverse cardiovascular events. Moreover, no broad cardio-protective effects can be concluded from the study. were included. All study subjects were followed for a period of 180 days from the date of index prescription. Atypical and typical users were matched on propensity score, calculated using pre-index demographics, clinical comorbidities, and medication use. A conditional logistic regression model stratified on the propensity score-matched pair using the Greedy matching algorithm was used to compare the risk of hospitalization for VTE in new users of atypical and typical antipsychotic drugs. Sensitivity analysis in the unmatched cohort was performed using propensity score as a continuous, linear term in logistic regression. RESULTS: A total of 15,637 new users of atypical and 2,337 new users of typical antipsychotic drugs were identified. There were 472 (2.6%) individuals with a hospitalization for VTE during follow-up. 417 were atypical and 55 were typical antipsychotic users. A 1:1 propensity score match yielded 2,333 matched pairs (4,666 individuals). In the matched cohort, 55 typical and 64 atypical drug users were hospitalized for VTE in the follow up period. Compared to typical antipsychotic users, users of atypical antipsychotics were less likely to have A32 
PCV3 RISK OF HOSPITALIZATIONS FOR VENOUS THROMBOEMBOLISM IN ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC USERS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES: A CLAIMS DATA ANALYSIS
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OBJECTIVES:
To examine prophylaxis use as it relates to the clinical and economic burden of venous thromboembolism (VTE) in abdominal surgery patients. METHODS: A retrospective study (January 1, 2005 to December 31, 2007) was conducted using a subset of the MarketScan Hospital Drug Database and its linked outpatient files from the Market Scan Commercial and Medicare Supplemental database. Patients' demographics, clinical and discharge statuses were compared using Chi-square testing and standardized difference. Risk-adjusted healthcare visits and costs were estimated using the General Linear Model. Potential risk factors for VTE events were selected using the Cox Proportional Hazard Regression Model. RESULTS: In patients who underwent abdominal surgery (nϭ49,355), 24,473(49.59%) received anticoagulant therapy during their hospitalization and until 30 days after discharge. VTE events for patients who received anticoagulant prophylaxis were 4.63% versus 7.02% for patients who did not receive anticoagulant prophylaxis. Compared with patients without VTE in the 6-month follow-up period, patients with VTE were more likely to be older, have comorbid conditions including previous VTE, major and minor bleeding, and cancer, and to have higher baseline health care visits and costs. After risk adjustment for pre-specified covariates, inpatient costs ($16,677 vs. $10,774), outpatient costs ($15,426 vs. $7,424), pharmacy costs ($2,541 vs. $1,862), and readmission rates (0.23% vs. 0.12%) were higher in patients who had VTE. In the multivariate analysis, appropriate anticoagulant prophylaxis use was significantly associated with the reduced risk of VTE (HR: 0.515). CONCLUSIONS: The VTE event rate was lower for patients who received prophylaxis compared with those who did not. Since the health care costs of patients with an event were significantly higher than those of patients without an event, prophylaxis use is associated with lower health care costs. 
PCV5 PREVALENCE, INCIDENCE, AND OUTCOMES OF CRITICAL LIMB ISCHEMIA IN THE MEDICARE POPULATION IN THE UNITED STATES
Sanofi-Aventis Group, Paris, France
Critical limb ischemia (CLI) is a severe obstruction of the arteries that seriously decreases blood flow to the extremities resulting in amputation of the affected limb if left untreated. Despite the severity of the disease, there is a lack of data on prevalence, incidence and outcomes of CLI in the United States. OBJECTIVES: We conducted a large population-based study to directly estimate prevalence, incidence and outcomes of CLI in the United States. METHODS: Data from January 2006 to December 2008 were extracted from the U.S. Medicare dataset. We estimated 1) age, gender, race and diabetes-specific CLI prevalence and incidence rates using the direct standardization method, and 2) factors associated with occurrence of outcomes (leg revascularization, non-traumatic amputation, and mortality) among the CLI population, using the Cox proportional hazard regression model. RESULTS: A total of 68,074 patients were identified with eligible CLI ICD-9 codes in 2007 of whom 44.53% were diabetic. Analyzing 2 years of data, CLI prevalence and annual incidence rates in this elderly population were 0.23% (0.28% for male and 0.20% for female patients) and 0.20% (0.23% and 0.17%), respectively. Just as with prevalence, incidence increased sharply among beneficiaries aged 65-69 (0.13%) to Ն85 (0.31%), was around 2.3 times higher in black patients compared to white patients, and 8.6 times higher in diabetic patients compared to non-diabetic patients. The overall incidence rates of leg revascularization and non-traumatic amputation in the year after CLI diagnosis were 29.7% and 25.2%, respectively. Compared to revascularization, patients who are older, male, black, and have diabetes had a higher probability of amputation. 30.3% of the patients died within the first year after CLI diagnosis. CONCLUSIONS: This first U.S. nationwide-based study shows that prevalence, incidence and outcomes are different according to patients' socio-demographic characteristics and comorbidities, suggesting that CLI patient management varies among the U.S. population.
PCV6 ANALYSIS OF MYOCARDIAL INFARCTION RELATED CLINICAL OUTCOMES, HEALTH CARE UTILIZATION AND COSTS OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Wang L, Xie L, Baser O STATinMED Research, Ann Arbor, MI, USA OBJECTIVES: To estimate clinical outcomes, healthcare utilization and cost burden of patients who suffered a myocardial infarction during the 180 days after diagnosis of non-valvular atrial fibrillation (NVAF) and compare it with patients who did not suffer a myocardial infarction. METHODS: Based on 2005-2007 U.S. Medicare advantage insurance claim files, patients aged 65 years and older who have had two or more primary diagnoses for NVAF occurring within 30 days of one another were selected. The 180-day follow-up event rates, healthcare facility use and costs for patients with a myocardial infarction and those without were compared. Risk adjustment was performed using the propensity score matching method with the ProbChoice™ algorithm. RESULTS: In patients who were identified with NVAF (nϭ18,575), 258 (1.39%) suffered a myocardial infarction during the 180 days after NVAF diagnosis. Patients were not significantly different in terms of gender, region, and baseline comorbid conditions. After risk-adjustment for pre-specified covariates, mortality (10.08% vs. 0.39% pϽ0.0001), outpatient emergency room (ER) visits (82.56% vs. 48.06% pϽ0.0001), acute coronary syndrome (63 vs. 2/100 person years), ischemic stroke (31 vs. 4/100 person years), major bleeding (10 vs. 1/100 person years) and non-major clinical relevant bleeding (24 vs. 6/100 person years) were all higher for patients who suffered a myocardial infarction compared to those who did not. Besides inpatient costs ($26,646 vs. $9,393), risk-adjusted outpatient ER costs ($1,176 vs. $863) were also higher for myocardial infarction patients. The overall risk-adjusted difference in health care costs is significant ($36,584 vs. $10,366 pϽ0.0001) . CONCLUSIONS: Most of the adverse events analyzed were higher for patients who suffered a myocardial infarction after NVAF relative to patients who did not. Total health care utilization and costs were also significantly increased. 
PCV7 ANALYSIS OF TREATMENT PATTERNS AND COSTS FOR VENOUS THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENTS IN HOSPITALIZED MEDICALLY ILL PATIENTS
OBJECTIVES:
To examine the prophylaxis use, incidence of VTE, major bleeding, minor bleeding and associated economic burden over 90 days in hospitalized medically-ill patients. METHODS: A retrospective study (January 1, 2005 to December 31, 2007 was conducted using a subset of the MarketScan Hospital Drug Database and its linked outpatient files from the Market Scan Commercial and Medicare Supplemental database. Eligible patients were selected if they were continuously enrolled in their health plan for at least 180 days prior to and 90 days following the index hospital discharge date, which is hospitalization with a medically ill diagnosis. Prophylaxis use is defined as the admission date of index hospitalization to 30 days after index hospital discharge and before the date of their first VTE events. Patients' demographics, healthcare visits and costs were compared using Chisquare testing and standardized differences. Risk-adjusted total healthcare costs between patients with events and without were estimated using the General Linear Model. RESULTS: In patients who were identified as medically ill (nϭ12,077), 6,464(53.52%) received anticoagulant therapy during their hospitalization and until 30 days after discharge. Compared with patients who did not receive any anticoagulant prophylaxis, patients who received anticoagulant prophylaxis had significantly lower VTE events (1.47% vs. 3.58%, pϽ0.0001). Although there was no significant difference in rates of major bleeding and minor bleeding, after riskadjustment for pre-specified covariates, patients with outcome events were significantly associated with higher total health care costs (VTE: $40,523 vs. $17,698 pϽ0.0001; Major bleeding: $27,430 vs. $18,137 pϽ0.0001; Minor bleeding: $25,696 vs. $17,410 pϽ0.0001). CONCLUSIONS: Despite existing guidelines, few medically-ill patients are receiving anticoagulant prophylaxis. Appropriate anticoagulant prophylaxis use results in lower VTE event rates and total follow-up health care costs in hospitalized medically-ill patients.
PCV8 EVALUATION OF A SAFETY INITIATIVE AND OUTCOMES FOR PATIENTS ON STATIN-FIBRATE COMBINATION THERAPIES IN THE VETERANS AFFAIRS POPULATION
Yi T, Tran JN, Bounthavong M Veterans Affairs San Diego Healthcare System, San Diego, CA, USA OBJECTIVES: Due to the reported higher incidences of adverse events in patients on combination statins and fibrates compared to statins alone, the Veterans Affairs (VA) San Diego initiated an intervention to reduce the number of patients on combination therapies. This study aimed to evaluate the effectiveness and safety of statin-fibrate combination therapies within the VA population. METHODS: This was a retrospective cohort study of VA medical, pharmacy, and laboratory data. Patients on a statin and fibrate combination in June 2008 were selected and stratified based on continuation or discontinuation of combination therapy by June 2009. Hyperlipidemic measures, safety measures, and adverse events were obtained pre-and post-intervention. Chi-square and ANOVA tests were utilized to test between-group differences and paired t-tests were conducted to analyze within-group differences at pre-and post-intervention. Repeated measures regressions were used to assess longitudinal differences between groups over time. RESULTS: No differences in rates of cardiovascular disease were found between patients who continued and discontinued combination therapy at baseline and one year later. No incidences of rhabdomyolysis and pancreatitis were reported. Compared to those who continued combination therapy, those who discontinued combination therapy had significantly lower total cholesterol (184 versus 172 mg/dL, pϭ0.029), higher CK (171 versus 132 U/L, pϭ0.006), and lower triglyceride levels post-intervention. There were no significant longitudinal differences between groups over time. Within the patients who discontinued combination therapy, AST and ALT were significantly lower after the intervention while total cholesterol and LDL levels were higher post-intervention. Within those who continued, ALT was lower while total cholesterol, LDL, and CK were higher post-intervention. CONCLUSIONS: Discontinuation of statin-fibrate combination therapy did not have a significant impact on the management of hyperlipidemia measures and no differences in adverse events were observed. Further studies should be done to assess the longterm effects of statin-fibrate combination therapy. 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4 
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